Mission Statement

We are a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology that function at the DNA level. Our Mission is to develop these small-molecule compounds to treat cancer and stroke in patients with the greatest unmet medical needs.  We are committed to the highest standards of scientific excellence and integrity to accomplish these goals for patients, shareholders and society.

Our corporate values exhibit our commitment to society:

Scientific Excellence:

We value innovation, creativity and individual initiative.


We rely on collaborative relationships and collective success.


We strive for honesty and transparency in our conduct, every day.

Mutual Admiration:

We seek to recognize and acknowledge every individual’s success.


We are committed to performing reliably and delivering on our commitments in all our work.


We persevere in achieving excellence in all we do with widespread enthusiasm.


April 10th, 2018

Rich Pharmaceuticals Explains How Targeted Immunotherapy Aids in the Treatment and Recovery of AML Patients
View Release

March 14th, 2018

Rich Pharmaceuticals’ Study Drug RP-323 (TPA) is a Potential Therapeutic Agent for the Treatment of Hodgkin’s Lymphoma
View Release

March 6th, 2018

Rich Pharmaceuticals’ Study Drug RP-323 (TPA) Elevates White Blood Cells (WBCs) Which Play a Vital Role Fighting Infections, and in Immunotherapy
View Release

» View All News

Stock Price